1. Estimates of benefits and harms of prophylactic use of aspirin in the general population.

    Annals of Oncology 26(1):47 (2015) PMID 25096604 PMCID PMC4269341

    Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population. The effect of aspirin for site-specific cancer ...
  2. Chemoprevention of breast and prostate cancers: where do we stand?

    Annals of Oncology 19 Suppl 7:vii234 (2008) PMID 18790958

  3. The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical Oncology.

    Annals of Oncology 19(6):1033 (2008) PMID 18508858

  4. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment.

    Annals of Oncology 17(5):801 (2006) PMID 16507565

    Hormonal treatment for women with breast cancer is frequently proposed in the adjuvant as well as in the palliative setting. Therefore, many women are confronted with early menopause and prolonged oestrogen deprivation and consequently with a variety of quality of life issues, such as menopausal...
  5. [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].

    Gynäkologisch-geburtshilfliche Rundschau 45(3):143 (2005) PMID 15990439

    More than 4,000 participants attended the congress and the consensus conference 2005, an increase of more than 1,000 participants. The conference had 2 highlights. (1) The presentation of the first results of the study BIG 1-98 -- letrozole as adjuvant, endocrine therapy in postmenopausal women ...
  6. Insulin-like growth factors and breast cancer.

    Onkologie 26(3):290 (2003) PMID 12845216

    The insulin-like growth factor (IGF) system performs multiple functions in normal tissue. IGFs are involved in normal mammary gland development, but have also been implicated in the pathogenesis of breast cancer. Epidemiological studies found an association between elevated serum levels of IGF-I...
  7. Optimal comprehensive symptom control: an overall strategy.

    European Journal of Cancer 37 Suppl 7:S261 (2001) PMID 11887999

  8. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

    Journal of Clinical Oncology 19(18):3817 (2001) PMID 11559719

  9. BRCA1/2 mutations in Swiss patients with familial or early-onset breast and ovarian cancer.

    Swiss medical weekly : official journal of the ... 131(15-16):223 (2001) PMID 11400546

    Germ-line alterations in BRCA1 and BRCA2 genes account for 30-50% of all forms of familial breast and ovarian cancer syndromes. Specific mutations in specific populations and ethnic groups have been identified in BRCA1 and BRCA2. However, it is not known whether such specific mutations prevail i...
    PDF not found
  10. Identifying breast cancer patients at high risk for bone metastases.

    Journal of Clinical Oncology 18(23):3925 (2000) PMID 11099322

    To identify patient populations at high risk for bone metastases at any time after diagnosis of operable breast cancer, because these patients are potential beneficiaries of treatment with bisphosphonates. We evaluated data from 6,792 patients who were randomized in International Breast Cancer S...
  11. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

    Journal of Clinical Oncology 18(7):1412 (2000) PMID 10735888

    Information on the tolerability and efficacy of adjuvant chemoendocrine therapy for older women is limited. We studied these issues using the data collected as part of the International Breast Cancer Study Group Trial VII. Postmenopausal women with operable, node-positive breast cancer were rand...
  12. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

    Journal of Clinical Oncology 17(5):1413 (1999) PMID 10334526

    This phase III study compared docetaxel with mitomycin plus vinblastine (MV) in patients with metastatic breast cancer (MBC) progressing despite previous anthracycline-containing chemotherapy. Patients (n=392) were randomized to receive either docetaxel 100 mg/m2 intravenously (i.v.) every 3 wee...
  13. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients.

    Supportive Care Cancer 7(3):149 (1999) PMID 10335933

    The effects and interaction of endocrine and cytotoxic adjuvant treatment on measures of cellular immunity were assessed in 41 stage I-II breast cancer patients from International Breast Cancer Study Group trials. Counts of lymphocytes and lymphocyte subsets [(T, T4, T8, B, natural killer (NK) a...
  14. How about trying even harder...?

    Supportive Care Cancer 7(2):59 (1999) PMID 10089081

  15. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial.

    Supportive Care Cancer 7(1):21 (1999) PMID 9926970

    The aim of this double-blind, randomized study was to compare the effects of two pamidronate dosages, given as repeated infusions in patients with advanced malignant osteolytic bone disease and bone pain. Seventy patients were randomly assigned to receive pamidronate 60 mg or 90 mg i.v. every 3 ...
  16. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.

    Clinical Chemistry and Laboratory Medicine 36(11):879 (1998) PMID 9877095

    Seventy cancer patients with malignant osteolytic bone disease received pamidronate every three weeks for a maximum of six cycles. Bone resorption parameters, urinary calcium excretion, and pain parameters were assessed at baseline and throughout the study. At baseline, 80-95% of patients showed...
  17. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG).

    British Journal of Cancer 78(5):686 (1998) PMID 9744512 PMCID PMC2063054

    Quality of life (QL) is used to assess treatments in clinical trials but may be influenced by other factors. We analysed the impact of biomedical, sociodemographic and cultural factors on baseline QL indicators in two International Breast Cancer Study Group trials. Patients with stage II breast ...
  18. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.

    Supportive Care Cancer 6(4):402 (1998) PMID 9695210

    Between July 1993 and September 1996, 107 consecutive febrile episodes in 83 neutropenic cancer patients with a median age of 41 years were randomized to treatment either with piperacillin/tazobactam 4.5 g every 8 h i.v. or ceftazidime 2 g every 8 h plus amikacin 15 mg/kg i.v. per day. In the ca...
  19. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

    European Journal of Cancer 34(5):632 (1998) PMID 9713266

    Adjuvant chemotherapy-induced amenorrhoea has been shown to be associated with reduced relapses and improved survival for premenopausal breast cancer patients. Amenorrhoea was, therefore, studied to define features of chemotherapy (i.e. duration and timing) and disease-related factors which are ...
  20. International Consensus Panel on the treatment of primary breast cancer. V: Update 1998.

    Recent results in cancer research. Fortschritte... 152:481 (1998) PMID 9928582